Lantern Pharma Inc. reported its financial results for the second quarter of 2025, revealing a net loss of approximately $4.33 million, or $0.40 per share, compared to a net loss of $4.96 million, or $0.46 per share, for the same period in 2024. For the six months ended June 30, 2025, the company incurred a net loss of $8.87 million, down from $10.40 million in the prior year. Total operating expenses for the second quarter were approximately $4.65 million, a decrease from $5.41 million in the same quarter of 2024, primarily due to reduced research and development costs.
The company’s total assets as of June 30, 2025, were approximately $17.42 million, a significant decline from $25.57 million at the end of 2024. This decrease was largely attributed to a reduction in cash and cash equivalents, which fell to $6.06 million from $7.51 million. Marketable securities also decreased to $9.84 million from $16.50 million. Current liabilities increased slightly to $4.88 million from $4.33 million, reflecting a rise in accounts payable and accrued expenses.
In terms of strategic developments, Lantern Pharma continues to advance its clinical programs, including three lead drug candidates: LP-300, LP-184, and LP-284. The company has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus on the development of LP-184 for central nervous system and brain cancer indications. The RADR® platform, which utilizes artificial intelligence to enhance drug discovery, now includes over 200 billion data points and is integral to the company’s strategy of identifying and developing targeted therapies.
Operationally, Lantern Pharma reported a decrease in research and development expenses, which totaled approximately $3.07 million for the second quarter, down from $3.89 million in the prior year. The company is actively pursuing additional funding avenues, including an at-the-market sales agreement that allows for the sale of up to $15.53 million in common stock. As of June 30, 2025, the company had working capital of approximately $12.32 million, which it believes will support operations into mid-2026, although it acknowledges the need for substantial additional funding to continue its research and development efforts.
Looking ahead, Lantern Pharma anticipates ongoing losses as it continues to invest in its drug development pipeline. The company plans to conduct additional clinical trials and expand its portfolio of drug candidates, which may require significant capital. Management has indicated that the ability to raise funds will be critical to the company’s future operations and success in bringing its therapies to market.
About Lantern Pharma Inc.
Lantern Pharma Inc. is an AI-driven biopharmaceutical company focused on developing targeted cancer therapies. Its proprietary RADR platform analyzes vast genomic and clinical data to identify and rescue promising drug candidates, including small molecules and antibody-drug conjugates. The company targets oncology markets with personalized, biomarker-driven treatments, leveraging data science to accelerate drug discovery, reduce costs, and improve patient outcomes in solid tumors and blood cancers.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov